SE9801148D0 - New receptors - Google Patents

New receptors

Info

Publication number
SE9801148D0
SE9801148D0 SE9801148A SE9801148A SE9801148D0 SE 9801148 D0 SE9801148 D0 SE 9801148D0 SE 9801148 A SE9801148 A SE 9801148A SE 9801148 A SE9801148 A SE 9801148A SE 9801148 D0 SE9801148 D0 SE 9801148D0
Authority
SE
Sweden
Prior art keywords
vdrr
polypeptides
methods
polypeptide
novel
Prior art date
Application number
SE9801148A
Other languages
Swedish (sv)
Inventor
Anders Berkenstam
Mats Dahlberg
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9703745A external-priority patent/SE9703745D0/en
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9801148A priority Critical patent/SE9801148D0/en
Publication of SE9801148D0 publication Critical patent/SE9801148D0/en
Priority to EP98941985A priority patent/EP1023323A1/en
Priority to CNB988112264A priority patent/CN1134452C/en
Priority to PCT/SE1998/001548 priority patent/WO1999019354A1/en
Priority to CA002306453A priority patent/CA2306453A1/en
Priority to AU90131/98A priority patent/AU732079B2/en
Priority to NZ504025A priority patent/NZ504025A/en
Priority to KR1020007004011A priority patent/KR20010031120A/en
Priority to US09/143,828 priority patent/US7118885B2/en
Priority to JP2000515925A priority patent/JP2001519441A/en
Priority to US11/369,263 priority patent/US20060228778A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRR gamma , which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.
SE9801148A 1997-10-14 1998-03-31 New receptors SE9801148D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9801148A SE9801148D0 (en) 1997-10-14 1998-03-31 New receptors
JP2000515925A JP2001519441A (en) 1997-10-14 1998-08-31 Novel vitamin D receptor-related polypeptides, nucleic acid sequences encoding such polypeptides and uses thereof
US09/143,828 US7118885B2 (en) 1997-10-14 1998-08-31 Nucleic acid encoding vitamin D receptor related polypeptide
PCT/SE1998/001548 WO1999019354A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
CNB988112264A CN1134452C (en) 1997-10-14 1998-08-31 Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
EP98941985A EP1023323A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
CA002306453A CA2306453A1 (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
AU90131/98A AU732079B2 (en) 1997-10-14 1998-08-31 Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
NZ504025A NZ504025A (en) 1997-10-14 1998-08-31 Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
KR1020007004011A KR20010031120A (en) 1997-10-14 1998-08-31 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
US11/369,263 US20060228778A1 (en) 1997-10-14 2006-03-06 Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703745A SE9703745D0 (en) 1997-10-14 1997-10-14 New receptors
SE9801148A SE9801148D0 (en) 1997-10-14 1998-03-31 New receptors

Publications (1)

Publication Number Publication Date
SE9801148D0 true SE9801148D0 (en) 1998-03-31

Family

ID=26663102

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801148A SE9801148D0 (en) 1997-10-14 1998-03-31 New receptors

Country Status (9)

Country Link
EP (1) EP1023323A1 (en)
JP (1) JP2001519441A (en)
KR (1) KR20010031120A (en)
CN (1) CN1134452C (en)
AU (1) AU732079B2 (en)
CA (1) CA2306453A1 (en)
NZ (1) NZ504025A (en)
SE (1) SE9801148D0 (en)
WO (1) WO1999019354A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508393A (en) * 1997-12-12 2002-03-19 メルク エンド カムパニー インコーポレーテッド DNA molecules encoding human nuclear receptor proteins nNR7 and nNR7-1
AU2003200641B2 (en) * 1998-01-09 2008-04-03 The Salk Institute For Biological Studies Novel Steroid-activated Nuclear Receptors and Uses therefor
US6911537B2 (en) * 1998-01-09 2005-06-28 The Salk Institute For Biological Studies Xenobiotic compound modulated expression systems and uses therefor
US6984773B1 (en) 1998-01-09 2006-01-10 The Salk Institute For Biological Studies Transgenic mice expressing a human SXR receptor polypeptide
US6756491B2 (en) * 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
WO1999048915A1 (en) * 1998-03-27 1999-09-30 Glaxo Group Limited Orphan nuclear receptor
US7238491B1 (en) 1998-03-27 2007-07-03 Smithkline Beecham Corporation Pregnane X receptor method
FR2801311B1 (en) * 1999-11-22 2005-08-26 Centre Nat Rech Scient POLYPEPTIDES DERIVED FROM THE NUCLEAR RECEPTOR OF VITAMIN D, AND USES THEREOF IN PARTICULAR IN THE SCREENING OF ANALOGUES OF VITAMIN D
AU2006200258B2 (en) * 1999-12-09 2009-04-09 The Salk Institute For Biological Studies Novel steroid-activated nuclear receptors and uses therefor
US6514941B1 (en) 1999-12-10 2003-02-04 Campina Melkunie B.V. Method of preparing a casein hydrolysate enriched in anti-hypertensive peptides
US20040053866A1 (en) * 2002-08-21 2004-03-18 The Regents Of The University Of California Tumor suppressor genes and their uses
SE0400489D0 (en) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407462A4 (en) * 1988-03-30 1992-02-05 Arch Development Corporation Dna binding proteins including androgen receptor
ATE215601T1 (en) * 1991-09-17 2002-04-15 Salk Inst For Biological Studi RECEPTORS OF THE STEROID/THYROID SUPERFAMILY OF RECEPTORS
US5756448A (en) * 1992-02-26 1998-05-26 The General Hospital Corporation Constitute activator of retinoid (CAR) receptor polypeptides
WO1996022390A1 (en) * 1995-01-17 1996-07-25 The Salk Institute For Biological Studies Methods, polypeptides, nucleotide sequence of xor-6, a vitamin d-like receptor from xenopus
AU5426596A (en) * 1995-05-16 1996-11-29 Salk Institute For Biological Studies, The Modulators for new members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
EP1023323A1 (en) 2000-08-02
WO1999019354A1 (en) 1999-04-22
NZ504025A (en) 2003-04-29
WO1999019354A9 (en) 1999-12-02
CA2306453A1 (en) 1999-04-22
CN1134452C (en) 2004-01-14
CN1279689A (en) 2001-01-10
KR20010031120A (en) 2001-04-16
AU9013198A (en) 1999-05-03
AU732079B2 (en) 2001-04-12
JP2001519441A (en) 2001-10-23

Similar Documents

Publication Publication Date Title
Skowyra et al. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex
Watterson et al. Structural similarities between the Ca2+-dependent regulatory proteins of 3': 5'-cyclic nucleotide phosphodiesterase and actomyosin ATPase.
ATE215601T1 (en) RECEPTORS OF THE STEROID/THYROID SUPERFAMILY OF RECEPTORS
Teichmann et al. Human TATA-binding protein-related factor-2 (hTRF2) stably associates with hTFIIA in HeLa cells
Todorov et al. Characterization of a cancer cachectic factor
LaRochelle et al. PDGF-D, a new protease-activated growth factor
Tesson et al. Localization of I2-Imidazoline Binding Sites on Monoamine Oxidases (∗)
Zhou et al. Cloning and functional characterization of a Brassica napus transporter that is able to transport nitrate and histidine
Reubi et al. SST3-selective potent peptidic somatostatin receptor antagonists
Jacobsen et al. Differential targeting of nicotinic acetylcholine receptors by novel αA-conotoxins
SE9801148D0 (en) New receptors
TR200200440T2 (en) Compositions and methods to increase the outflow of cholesterol and increase HDL using ATP Binding Cassette Transporter Protein ABC1
ATE191503T1 (en) SOMATOSTATIN RECEPTORS
DE69836956D1 (en) RECEPTOR 5 CONTAINING A DOMAIN RESPONSIBLE FOR CELL DEATH
PT101297A (en) GLITARY MITOGENIC FACTORS, THEIR PREPARATION AND UTILIZATION
DE69839340D1 (en) Mutants of the VASCULAR, ENDOTHELCELL SPECIFIC GROWTH FACTOR C (VEGF-C) AND THEIR USES
HUP0105337A2 (en) Polypeptides involved in immune response
ATE106940T1 (en) NUCLEIC ACID ENCODING THE T-CELL ANTIGEN RECEPTOR POLYPEPTIDE.
Bernat et al. Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization
PT973794E (en) NETRINA RECEPTORS
MXPA02008239A (en) Human schizophrenia gene.
Okamoto et al. Insulin-like growth factor-II/mannose 6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose 6-phosphate, but capable in response to insulin-like growth factor-II
ATE351905T1 (en) MITOGENE REGULATORS
WO1994028132A3 (en) Opioid receptors: compositions and methods
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof